Does Rallies show Form 4 insider transactions for ANIX?

Yes. Rallies tracks ANIX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ANIX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ANIX. It does not provide personalized investment advice.

ANIX (Anixa Biosciences, Inc.) Stock Analysis - Insider Trades

Anixa Biosciences, Inc. (ANIX) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIX trades at $2.79 with a market cap of $92.54M and a P/E ratio of -8.04. ANIX moved +3.18% today. Year to date, ANIX is -14.15%; over the trailing twelve months it is +4.60%. Its 52-week range spans $2.07 to $5.46. Analyst consensus is buy with an average price target of $14.00. Rallies surfaces ANIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ANIX stock inside the company?

Recent ANIX insider activity includes Baskies Arnold M bought 10.00K, Titterton Lewis H jr bought 10.00K, KUMAR AMIT bought 5.00K, Baskies Arnold M bought 5.00K, and Titterton Lewis H jr bought 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ANIX Key Metrics

Key financial metrics for ANIX
Metric	Value
Price	$2.79
Market Cap	$92.54M
P/E Ratio	-8.04
EPS	$-0.34
Dividend Yield	0.00%
52-Week High	$5.46
52-Week Low	$2.07
Volume	34
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-11.03M
Gross Margin	0.00%

Recent ANIX Insider Trades

Baskies Arnold M bought 10.00K (~$30.40K) on Jan 28, 2026.
Titterton Lewis H jr bought 10.00K (~$30.80K) on Jul 31, 2025.
KUMAR AMIT bought 5.00K (~$15.80K) on Jul 30, 2025.
Baskies Arnold M bought 5.00K (~$16.95K) on Jul 18, 2025.
Titterton Lewis H jr bought 10.00K (~$31.40K) on Jul 11, 2025.

Latest ANIX News

Anixa Biosciences’ CAR-T Patients Survive up to 28 Months in Phase 1 Trial — May 11, 2026
Anixa Biosciences Secures Mexican Patent Extending Vaccine Protection into 2040 — Apr 29, 2026
Anixa to Present Positive Phase 1 Lira-cel Survival Data at ISCT Meeting — Apr 22, 2026
Anixa Biosciences Reports 74% Immune Response and Lira-Cel Survival Data — Apr 9, 2026
Anixa Secures Cytovance Deal After Phase 1 Yields 74% Immune Response — Apr 1, 2026

ANIX Analyst Consensus

1 analysts cover ANIX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.00.

Common questions about ANIX

Who is trading ANIX stock inside the company?: Recent ANIX insider activity includes Baskies Arnold M bought 10.00K, Titterton Lewis H jr bought 10.00K, KUMAR AMIT bought 5.00K, Baskies Arnold M bought 5.00K, and Titterton Lewis H jr bought 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ANIX?: Yes. Rallies tracks ANIX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ANIX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ANIX. It does not provide personalized investment advice.